ArticleAnales del sistema sanitario de Navarra2026
[Treatment with dabrafenib and trametinib in an intrahepatic cholangiocarcinoma harboring a BRAF V600E mutation].
Article in Anales del sistema sanitario de Navarra, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intrahepatic cholangiocarcinoma is a poor prognosis malignancy with limited therapeutic options in advanced stages. Identification of actionable molecular alterations may enable targeted therapies in selected patients. We describe a 74-year-old man with metastatic intrahepatic cholangiocarcinoma harboring a BRAF V600E mutation, treated off-label in the second-line setting with dabrafenib (150 mg twice daily) plus trametinib (2 mg once daily) after progression on platinum-based chemotherapy. Treatment resulted in stable disease, a reduction in CA 19-9, and mild adverse events. Progression-free survival was 12.8 months and overall survival reached 44.4 months. This case underscores the importance of early molecular profiling and supports the integration of targeted therapies into routine clinical practice for tumors with limited effective therapeutic options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.